The Czech Competition Office clears in a landmark decision in phase II a merger in the pharmaceutical sector subject to several structural and behavioural remedies, including transfer and divestment of trademarks and termination of a license agreement (Zentiva / S. L. Pharma)

Valentová, Eva

Previous article The Danish Competition Council conditionally approves the creation of a three-partner joint venture in the markets for classified online advertising for cars, real property and travel (Zonerne - Metropol Online / Det Faelles Udgiverselskab/TV2) Next article The Italian Competition Authority revokes remedies originally imposed to the parties to a merger by interpretating extensively the notion of de facto control (Società Assicuratrice Industriale / La Fondiaria Assicurazioni)

13 Jun 2003

The Czech Competition Office clears in a landmark decision in phase II a merger in the pharmaceutical sector subject to several structural and behavioural remedies, including transfer and divestment of trademarks and termination of a license agreement (Zentiva / S. L. Pharma)

KEYWORDS

Reference

Czech Competition Office, Zentiva /S.L. PHARMA HOLDING, S 180/2-2090/03, 13 June 2003 (Czech)

The operation On the basis of share transfer agreement concluded on 20 January 2003, ZENTIVA B.V. ("Zentiva") acquired 100 % of shares in S.L. PHARMA HOLDING GESELLSCHAFT M.B.H. ("SLP") and therefore gained a sole control over the company. Zentiva operates in Czech Republic mainly through Léèivá, a.s., a producer of pharmaceutical preparations. SLP is a controlling company of Slovakofarma, the main producer of pharmaceutical preparations in Slovakia, with substantial share at the Czech market. The market(s) For the purpose of identifying the relevant market, the Office referred to the Anatomical classification (ATC) used by European Pharmaceutical Market Research Association (EphMRA), specifically the ATC-3 level of classification, based on therapeutic indication (i.e. intended use)

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Eva Valentová
Prague City Hall

13 contributions 29587 visits

Quotation

Eva Valentová, The Czech Competition Office clears in a landmark decision in phase II a merger in the pharmaceutical sector subject to several structural and behavioural remedies, including transfer and divestment of trademarks and termination of a license agreement (Zentiva / S. L. Pharma), 13 June 2003, e-Competitions June 2003, Art. N° 20907

Visites 2490